The role of maternal toxicity in lovastatin-induced developmental toxicity

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 71, Issue 3, 2004, Pages 111-123

  Lankas, George R ^a   Cukierski, Mark A ^a   Wise, L David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Developmental toxicity; Lovastatin; Maternal toxicity; Pharmaceuticals; Safety assessment

Indexed keywords

MEVINOLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; FEMALE; FETUS WEIGHT; FOOD INTAKE; FORESTOMACH; MORBIDITY; MORTALITY; NONHUMAN; NUTRITIONAL DEFICIENCY; OSSIFICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RAT; SKELETON MALFORMATION; STOMACH LESION; TERATOGENESIS; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ANIMALS; AREA UNDER CURVE; BODY WEIGHT; BONE AND BONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; EMBRYO; FEMALE; FETAL WEIGHT; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LOVASTATIN; MATERNAL EXPOSURE; ORGAN SIZE; PREGNANCY; PREGNANCY, ANIMAL; RATS; TERATOGENS; TIME FACTORS; WEIGHT LOSS;

EID: 3543088079     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20005     Document Type: Article

References (31)

1. Belknap WM, Dietschy JM. 1988. Sterol synthesis and low density lipoprotein clearance in vivo in the pregnant rat, placenta, and fetus. J Clin Invest 82:2077-2085.
2. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, Beachy PA. 1996. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383:407-413.
3. Cooper MK, Porter JA, Young KE, Beachy PA. 1998. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280:1603-1607.
4. Cooper MK, Wassif CA, Krakowiak PA, Taipale J, Gong R, Kelley RI, Porter FD, Beachy PA. 2003. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nature Genetics 33:508-513.
5. Dostal LA, Schardein JL, Anderson JA. 1994. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 50:387-394.
6. Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S. 1989. The physiological disposition of lovastatin. Drug metabolism and Disposition of the Biological Fate of Chemicals 17:166-173.
7. Fan CM, Tessier-Lavigne M. 1994. Patterning of mammalian somites by surface ectoderm and notochord: evidence for sclerotome induction by a hedgehog homolog. Cell 79:1175-1186.
8. Farese RV Jr., Herz J. 1998. Cholesterol metabolism and embryogenesis. Trends Genet 14:115-120.
9. Goetz JA, Suber LM, Zeng X, Robbins DJ. 2002. Sonic Hedgehog as a mediator of long-range signaling. BioEssays. 24:157-165.
10. Harter HL. 1961. Expected values of normal order statistics. Biometrika 48:151-165.
11. Henck JW, Craft WR, Black A, Colgin J, Anderson JA. 1998. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastain in rats. Toxicol Sci 41:88-99.
12. Hickory W, Nanda R, Catalanotto FA. 1979. Fetal skeletal malformations associated with moderate zinc deficiency during pregnancy. J Nutr 109:883-891.
13. Hrab RV, Hartman, HA, and Cox, RH Jr. 1994. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 50:19-26.
14. Incardona JP, Gaffield W, Kapur RP, Roelink H. 1998. The teratogenic Veratrum alkaloid cyclopamine inhbits Sonic hedgehog signal transduction. Development 125:3553-3562.
15. Kloss MW, Patrick DH, MacDonald JS. 1991. Studies on the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the rodent forestomach. Fd Chem Tox 29:621-628.
16. MacDonald JS, Gerson RJ, Kornbrust DJ, Moss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL. 1988. Preclinical evaluation of lovastatin. Am J Cardiol 62:16J-27J.
17. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. 1996. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 10:439-446.
18. Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. 1983. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Teratology 28:449-456.
19. Nybakken K, Perrimon N. 2002. Hedgehog signal transduction: recent findings. Curr Opin Genet Dev. 12:503-511.
20. Peters PWJ. 1981. Development of the rat skeleton. Teratology 24:45A.
21. Porter JA, Young KE, Beachy PA. 1996a. Cholesterol modification of Hedgehog signaling proteins in animal development. Science 274:255-259.
22. Porter JA, Ekker, S, Park WJ, von Kessler DP, Young KE, Chen CH, Ma Y, Woods AS, Cotter RJ, Koonin EV, Beachy PA. 1996b. Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Cell 86:21-34.
23. Roessler E, Belloni E, Gaudenz K, Jay P, Berta P, Scherer SW, Tsui LC, Muenke M. 1996. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 14:357-360.
24. Roux C, Aubry M. 1966. Action teratogene chez le rat d'un inhibiteur dela synthses du cholesterol, le AY 9944. CR Seances Soc Biol Fil 160:1353-1357.
25. Salen G, Shefer S, Batta AK, Tint GS, Xu G, Honda A, Irons M, Elias ER. 1996. Abnormal cholesterol biosynthesis in the Smith-Lemli-Opitz syndrome. J Lipid Res 37:1169-1180.
26. Singer I, Scott S, Kazazis DM, Huff JW. 1988. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat heptocytes. PNAS 85:5264-5268.
27. Tanabe Y, Jessell TM. 1996. Diversity and pattern in the developing spinal cord. Science 274:1115-1123.
28. Tobert JA. 2003. Lovastatin and beyond: the history of the HMG-CoA reductast inhibitors. Nature Rev 2:517-526.
29. Tukey JW. 1962. The future of data analysis. Ann Math Stat 33:1-67.
30. Tukey JW, Ciminera JL, Heyse JF. 1985. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41:295-301.
31. von Keutz E, Schluter G. 1998. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am J Cardiol 82:11J-17J.